# A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Study · id `cardio:ct-nct05254002` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05254002](<https://clinicaltrials.gov/study/NCT05254002>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05254002

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1664 participants.

## Technical summary

Registry record NCT05254002. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-23 (actual); primary completion 2025-03-14 (actual). Results posted on 2026-07-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1664 participants (enrolled count; ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Started: 2022-06-23 (actual) (ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Primary completion: 2025-03-14 (actual) (ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Completion: 2025-03-17 (actual) (ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Results first posted: 2026-07-13 (ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; Denmark; France; Germany; India; Israel; Italy; Japan; Netherlands; South Korea; Spain; Taiwan (ClinicalTrials.gov record NCT05254002, source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05254002-2026-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Acronym: CONFIDENCE
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Disease
- Intervention (Drug): Finerenone (BAY94-8862 ) 10 mg
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Empagliflozin Placebo
- Intervention (Drug): Finerenone (BAY94-8862 ) 20 mg
- Intervention (Drug): Finerenone Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics (`cardio:pubmed-39916475`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (`cardio:pubmed-40470996`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial (`cardio:pubmed-40886054`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial (`cardio:pubmed-41493296`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone (`cardio:pubmed-41905767`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure (`cardio:pubmed-42244376`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 68ff3b198ca60c735dec4f3ae6a372bd2eb0d96ab5194d5c124af847b73a6ead
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
